ATE193893T1 - Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes - Google Patents

Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes

Info

Publication number
ATE193893T1
ATE193893T1 AT95916141T AT95916141T ATE193893T1 AT E193893 T1 ATE193893 T1 AT E193893T1 AT 95916141 T AT95916141 T AT 95916141T AT 95916141 T AT95916141 T AT 95916141T AT E193893 T1 ATE193893 T1 AT E193893T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
cytotoxic
hcv
lymphocytes
Prior art date
Application number
AT95916141T
Other languages
English (en)
Inventor
Jay A Berzofsky
Stephen Feinstone
Mutsunori Shirai
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22843009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE193893(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE193893T1 publication Critical patent/ATE193893T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95916141T 1994-04-08 1995-04-07 Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes ATE193893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22497394A 1994-04-08 1994-04-08
PCT/US1995/003935 WO1995027733A1 (en) 1994-04-08 1995-04-07 Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure

Publications (1)

Publication Number Publication Date
ATE193893T1 true ATE193893T1 (de) 2000-06-15

Family

ID=22843009

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916141T ATE193893T1 (de) 1994-04-08 1995-04-07 Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes

Country Status (7)

Country Link
EP (1) EP0754193B1 (de)
JP (1) JPH10503473A (de)
AT (1) ATE193893T1 (de)
AU (1) AU697171B2 (de)
CA (1) CA2187299A1 (de)
DE (1) DE69517521T2 (de)
WO (1) WO1995027733A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE69935599T2 (de) 1998-08-21 2007-11-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Modifizierte hcv peptid-impfstoffe
GB9825951D0 (en) * 1998-11-26 1999-01-20 Medical Res Council Viral therapeutics
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP1608402B1 (de) 2003-03-24 2010-10-20 Intercell AG Verbesserte impfstoffe
JP4734241B2 (ja) 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
WO2006080340A1 (ja) * 2005-01-28 2006-08-03 Green Peptide Co., Ltd. Ｃ型肝炎ウイルス由来ペプチドとインターフェロンとの併用療法
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
EP2646459B1 (de) 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
IN2014KN02769A (de) 2012-06-06 2015-05-08 Bionor Immuno As

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
JPH06327482A (ja) * 1993-05-21 1994-11-29 Imuno Japan:Kk オリゴペプタイド、オリゴヌクレオチドならびにｃ型肝炎ウ イルス関連抗体検出方法
ATE236981T1 (de) * 1993-11-04 2003-04-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Also Published As

Publication number Publication date
EP0754193A1 (de) 1997-01-22
AU697171B2 (en) 1998-10-01
AU2274895A (en) 1995-10-30
WO1995027733A1 (en) 1995-10-19
EP0754193B1 (de) 2000-06-14
JPH10503473A (ja) 1998-03-31
DE69517521T2 (de) 2001-03-08
DE69517521D1 (de) 2000-07-20
CA2187299A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
ATE193893T1 (de) Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
DE69233736D1 (de) Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit
FI900808A0 (fi) Humant mannos bindande protein.
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
DE69531004D1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
ATE197403T1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE68600T1 (de) Satz und verfahren zur diagnose der iganephropathie.
ATE297983T1 (de) Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
SE9002212D0 (sv) Igg binding protein
IL156799A (en) Peptides related to the GP120 viral protein and their uses
BR0012765A (pt) Peptìdeo, métodos de fabricar um anticorpo, de fabricar um agente de ligação capaz de ligar-se a uma forma celular de uma proteìna de prion, de remover uma forma celular de uma proteìna de prion de uma amostra, e de usar um anticorpo e/ou agente de ligação, anticorpo, agente de ligação, uso de um anticorpo ou agente de ligação, kit, e , sequência de peptìdeo de uma forma celular de uma proteìna de prion
ATE283281T1 (de) T-zell epitope des raygraspollen-allergens
DE69521985D1 (de) Diagnose und behandlung von streptococus oder enterococus infektionen
DE69326145D1 (de) Synthetische peptide für die behandlung von myasthenia gravis
ATE334145T1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
DE69531167D1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen-karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen